Kanilad

Lacosamide, the active ingredient in Kanilad, is an anticonvulsant presented as an oral formulation for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kanilad (lacosamide) is used within the antiepileptic drug class to manage focal seizure disorders.

Partial‑onset seizures: reduces seizure frequency when added to existing therapy. Adjunctive therapy in focal epilepsy: improves overall seizure control as an add‑on medication. Refractory focal seizures: offers an additional option for patients not responding to other antiepileptics.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild to moderate stomach upset. - Headache: tension‑type or throbbing pain. - Fatigue: feeling unusually tired. - Visual disturbances: blurred vision or double vision.

Serious or Rare Side Effects: - Cardiac arrhythmia: PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal ideation: thoughts of self‑harm. - Hepatic dysfunction: elevated liver enzymes. - Respiratory depression: difficulty breathing in severe cases.

When prescribing or dispensing Kanilad, consider the following safety measures.

Renal impairment: adjust therapy based on renal function. Cardiac monitoring: assess ECG for PR‑interval changes. Pregnancy: use only if benefits outweigh potential risks. Concomitant CNS depressants: monitor for enhanced sedation. Alcohol use: advise patients to limit intake. Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide levels. - Class III antiarrhythmics (e.g., amiodarone): increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Other antiepileptics (e.g., valproate, levetiracetam): may affect seizure control. - CNS depressants (e.g., benzodiazepines, opioids): monitor for additive sedation. - Alcohol: may enhance dizziness and drowsiness.